REV3L and metastatic malignant neoplasm in the lymph nodes: As shown in Table 3, patients carrying REV3L rs462779 TC or TT genotypes had a lower hazard (OR=0.38, 95% CI=0.17-0.89, P=0.025) of lymph node metastasis in the dominant model when compared with patients carrying CC genotype.